Research Paper|Volume 15, Issue 24|pp 15213—15227

A potential therapeutic approach for gastric cancer: inhibition of LACTB transcript 1

Wei Nie¹, Lihua Hu², Zhiqiang Yan³, Yang Wang³, Qianyun Shi², Shui He², Qian Wang³, Fang Yang^1,²

¹Center of Clinical Laboratories, The Affiliated Hospital of Guizhou Medical University, Guiyang, China
²Department of Basic Clinical Laboratory and Hematology, School of Clinical Laboratory Science, Guizhou Medical University, Guiyang, China
³Department of Gastrointestinal Surgery, Affiliated Hospital of Guizhou Medical University, Guiyang, China

* Equal contribution

Received: July 6, 2023Accepted: November 3, 2023Published: December 26, 2023

https://doi.org/10.18632/aging.205345

Copyright: © 2023 Nie et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Background: This study sought to investigate the role of LACTB transcript 1 in regulating adaptive immune resistance and stemness in gastric cancer and its potential as a therapeutic target for precision medicine.

Methods: Bioinformatics analysis and RT-qPCR were used to analyze the expression level of LACTB and its transcripts in gastric cancer cells. The effects of LACTB transcript 1 on adaptive immune resistance and stemness were evaluated using in vitro cell experiments and western blotting experiments.

Results: Our study findings revealed that LACTB transcript 1 modulated adaptive immune resistance and inhibited the stemness of gastric cancer cells. Knocking down the expression level of LACTB transcript 1 activated autophagy and inhibited EMT. As expected, overexpression of LACTB transcript 1 yielded the opposite findings. The expression level of LACTB transcript 1 in the peripheral blood of gastric cancer patients was consistent with the bioinformatics analysis, suggesting its potential as a biomarker of gastric cancer.

Conclusions: LACTB transcript 1 is a promising therapeutic target for precision medicine in gastric cancer by modulating immune evasion mechanisms and stemness. These findings provide insights into leveraging long non-coding RNAs (lncRNAs) in immunotherapy, radiotherapy, and chemotherapy to enhance cancer therapy efficacy, particularly in the context of targeting tumor heterogeneity and stemness.